Affimed N.V (AFMD), a clinical-stage biopharmaceutical company, is scheduled to host a conference call on Tuesday, December 17, 2024, to review clinical data from its AFM24-102 trial.
AFM24-102 is a Phase 1/2a dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGFR-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com